keyword
MENU ▼
Read by QxMD icon Read
search

gallium 68 PSMA

keyword
https://www.readbyqxmd.com/read/28775203/immunohistochemical-validation-of-psma-expression-measured-by-68-ga-psma-pet-ct-in-primary-prostate-cancer
#1
Nadine Woythal, Ruza Arsenic, Carsten Kempkensteffen, Kurt Miller, Jan-Carlo Janssen, Kai Huang, Marcus R Makowski, Winfried Brenner, Vikas Prasad
Aim: Gallium 68 ((68)Ga) prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) has a proven role in staging and restaging of prostate cancer (PCA) patients. The aims of this study were to evaluate the association of intraprostatic (68)Ga-PSMA PET/CT (PET) findings and prostate specific membrane antigen (PSMA) expression in immunohistochemical staining (IHC) and generate a cut-off value for the differentiation between benign prostate tissue from PCA. Methods: Data of 31 patients (mean 67...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28765999/a-rare-case-of-thymoma-first-detected-on-gallium-68-psma-pet-ct
#2
Hian Liang Huang, Angela Renayanti Dharmawan, Colin Jingxian Tan, Sue Ping Thang
No abstract text is available yet for this article.
August 1, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28753806/-68-ga-labeled-prostate-specific-membrane-antigen-ligand-positron-emission-tomography-computed-tomography-for-prostate-cancer-a-systematic-review-and-meta-analysis
#3
REVIEW
Finn E von Eyben, Maria Picchio, Rie von Eyben, Handoo Rhee, Glenn Bauman
CONTEXT: (68)Gallium prostate-specific membrane antigen (PSMA) ligand (68)Ga-HBED-CC-PSMA ((68)Ga-PSMA) is a promising radiotracer for positron emission tomography (PET)/computed tomography (CT) of prostate cancer. OBJECTIVE: To conduct a meta-analysis to evaluate detection rate, diagnostic test accuracy, and adverse effects of (68)Ga-PSMA PET/CT or PET/magnetic resonance imaging (MRI) for staging of prostate cancer and for restaging of rising prostate-specific antigen (PSA) after initial treatment...
November 15, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28742337/gallium-complexation-stability-and-bioconjugation-of-1-4-7-triazacyclononane-derived-chelators-with-azaheterocyclic-arms
#4
Alexander Schmidtke, Tilman Läppchen, Christian Weinmann, Lorenz Bier-Schorr, Manfred Keller, Yvonne Kiefer, Jason P Holland, Mark D Bartholomä
We have recently introduced a 1,4,7-triazacyclononane (TACN) based chelating system with additional five-membered azaheterocyclic substituents for complexation of radioactive Cu(2+) ions. In this work, we investigated the complexation properties of these novel chelators with Ga(3+). In labeling experiments, we could show that the penta- and hexadentate imidazole derivatives NODIA-Me 4 and NOTI-Me 1 can be labeled with (68)Ga in specific activities up to ∼30 MBq nmol(-1), while the corresponding thiazole derivative NOTThia 2 did not label satisfactorily under identical conditions...
August 7, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28707038/-68-ga-psma-hbed-cc-uptake-in-osteolytic-osteoblastic-and-bone-marrow-metastases-of-prostate-cancer-patients
#5
Jan-Carlo Janssen, Nadine Woythal, Sebastian Meißner, Vikas Prasad, Winfried Brenner, Gerd Diederichs, Bernd Hamm, Marcus R Makowski
PURPOSE: The aim of this study was to evaluate potential differences in "Glu-NH-CO-NH-Lys" radio-labeled with [(68)Ga]gallium N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N-diacetic acid ([(68)Ga]PSMA-HBED-CC) uptake in osteolytic, osteoblastic, mixed, and bone marrow metastases in prostate cancer (PC) patients. PROCEDURES: This retrospective study was approved by the local ethics committee. Patients who received [(68)Ga]PSMA-HBED-CC positron emission tomography/computed tomography ([(68)Ga]PSMA-PET/CT) with at least one positive bone metastasis were included in this study...
July 13, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28685078/-68-ga-psma-pet-ct-for-the-detection-of-bone-metastasis-in-recurrent-prostate-cancer-and-a-psa-level-2-ng-ml-two-case-reports-and-a-literature-review
#6
Lars J Petersen, Julie B Nielsen, Katja Dettmann, Rune V Fisker, Uwe Haberkorn, Louise Stenholt, Helle D Zacho
Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28670175/a-comparative-study-of-68-gallium-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-and-magnetic-resonance-imaging-for-lymph-node-staging-in-high-risk-prostate-cancer-patients-an-initial-experience
#7
Manoj Gupta, Partha S Choudhury, Dibyamohan Hazarika, Sudhir Rawal
Lymph node staging plays an important role in planning initial management in nonmetastatic prostate cancer. This article compares the role of (68)Gallium ((68)Ga)-prostate specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) with magnetic resonance imaging (MRI), which is considered the standard staging modality. Out of 39 high-risk prostate cancer patients who underwent (68)Ga-PSMA PET-CT for staging (December 2014-December 2015), 12 patients underwent radical prostatectomy along with ePLND and were included in the analysis...
July 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28649735/diagnostic-sensitivity-of-tc-99m-hynic-psma-spect-ct-in-prostate-carcinoma-a-comparative-analysis-with-ga-68-psma-pet-ct
#8
Ismaheel O Lawal, Alfred O Ankrah, Neo P Mokgoro, Mariza Vorster, Alex Maes, Mike M Sathekge
BACKGROUND: Emerging data from published studies are demonstrating the superiority of Ga-68 PSMA PET/CT imaging in prostate cancer. However, the low yield of the Ge-68/Ga-68 from which Gallium-68 is obtained and fewer installed PET/CT systems compared to the SPECT imaging systems may limit its availability. We, therefore, evaluated in a head-to-head comparison, the diagnostic sensitivity of Ga-68 PSMA PET/CT and Tc-99m PSMA SPECT/CT in patients with prostate cancer. METHODS: A total of 14 patients with histologically confirmed prostate cancer were prospectively recruited to undergo Ga-68 PSMA PET/CT and Tc-99m HYNIC PSMA SPECT/CT...
August 2017: Prostate
https://www.readbyqxmd.com/read/28607878/targeted-prostate-biopsy-using-68-gallium-psma-pet-ct-for-image-guidance
#9
Demetrios N Simopoulos, Shyam Natarajan, Tonye A Jones, Wolfgang P Fendler, Anthony E Sisk, Leonard S Marks
Prostate specific membrane antigen (PSMA) scanning is a sensitive method of prostate cancer detection. In a 71 y.o. man with a PSA of 49 (6%F), 4 negative MRI studies and 6 negative biopsies over an 8 year interval, a (68)Ga-PSMA PET/CT scan showed a PSMA-avid spot in the prostate. Using image fusion technology, the lesion was target-biopsied and Gleason 3 + 4 = 7 (cancer core length of 12 mm) was identified. This case may herald a new application for PSMA scanning and prostate cancer imaging.
September 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28576423/-pet-ct-and-biochemical-recurrence-of-prostate-adenocarcinoma-added-value-of-68-ga-psma-11-when-18-f-fluorocholine-is-non-contributive
#10
M Gauthé, O Belissant, A Girard, J Zhang Yin, J Ohnona, A-S Cottereau, V Nataf, S Balogova, D Pontvert, T Lebret, B Guillonneau, O Cussenot, J-N Talbot
INTRODUCTION: Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose (18)F-fluorocholine (FCH) PET/CT was non-contributive. PATIENTS AND METHOD: Patients were prospectively included between April and December 2016. PET/CT was performed 60min after injection of 2MBq/kg of body mass of (68)Ga-PSMA-11...
June 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28551611/-68-ga-psma-pet-ct-has-a-role-in-detecting-prostate-cancer-lesions-in-patients-with-recurrent-disease
#11
REVIEW
Claire Fitzpatrick, Olwyn Lynch, Laure Marignol
BACKGROUND/AIM: Early detection of recurrent πrostate cancer (PCa) lesions is paramount to allow patients to avail of localised salvage therapy options. The most significant reason for failure of salvage therapy is undetected metastatic disease. This demonstrates the need for a more accurate monitoring tool. The prostate-specific membrane antigen (PSMA) is increasingly investigated as a novel tracer for gallium 68 PET/CT to detect PCa lesions in patients with recurrent disease. MATERIALS AND METHODS: The Embase, Pubmed and the Cochrane databases were searched to identify studies investigating the accuracy of (68)Ga-PSMA-PET/CT in detecting PCa lesions...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28548372/initial-multicentre-experience-of-68-gallium-psma-pet-ct-guided-robot-assisted-salvage-lymphadenectomy-acceptable-safety-profile-but-oncological-benefit-appears-limited
#12
Amila Siriwardana, James Thompson, Pim J van Leeuwen, Shaela Doig, Anton Kalsbeek, Louise Emmett, Warick Delprado, David Wong, Hemamali Samaratunga, Anne-Maree Haynes, Geoff Coughlin, Phillip Stricker
OBJECTIVES: To evaluate the safety and short-term oncological outcomes for (68) Ga-PSMA PET/CT directed robot-assisted salvage node dissection (RASND) for prostate cancer oligometastatic nodal recurrence. MATERIALS AND METHODS: Between February 2014 and April 2016, 35 patients across two centres underwent RASND for (68) Ga-PSMA PET/CT detected oligometastatic nodal recurrence. RASND was performed by targeted pelvic dissection, unilateral extended pelvic template or bilateral extended pelvic template dissection, depending on previous pelvic treatment and extent/location of nodal disease...
May 26, 2017: BJU International
https://www.readbyqxmd.com/read/28533638/clinical-utility-of-gallium-68-psma-pet-ct-scan-for-prostate-cancer
#13
Kumaraswamy G Kallur, Prashanth G Ramachandra, Krishnappa Rajkumar, Shivakumar S Swamy, Indiresh Desai, Raghavendra M Rao, Shekhar Gowda Patil, P S Sridhar, Nagaraj Madhusudhan, Raghunath S Krishnappa, Veerendra Bhadrasetty, Hemantha M Kumara, S D Santhosh, Basavalingaiah S Ajaikumar
BACKGROUND: Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. One of the important challenges in this cancer is to detect recurrent disease. Biochemical response using Prostate Specific Antigen (PSA) and Imaging using several PET tracers have poor sensitivity and specificity. Therefore, we analyse the role of Ga68-PSMA (Prostate Specific Membrane Antigen) imaging in prostate cancer, which is a new PET tracer. METHODS: In this study, we evaluated PET scans of 262 patients with diagnosis of prostate cancer...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28474140/comparison-of-psma-hbed-and-psma-i-t-as-diagnostic-agents-in-prostate-carcinoma
#14
Michael McCarthy, Tiffany Langton, Divesh Kumar, Andrew Campbell
PURPOSE: Gallium(68)-labelled prostate-specific membrane antigen (PSMA) radiopharmaceuticals can be used to detect prostate cancer (PCa) cells due the their over expression of PSMA. The (68)Ga HBED-PSMA (PSMA-HBED) ligand has been most widely used and can be considered the current gold standard agent. Further PSMA ligands based on the DOTAGA and DOTA conjugates have more recently been developed. These agents (PSMA-I&T and PSMA-617) have potential theranostic capabilities as they can be conjugated with therapeutic radioisotopes...
August 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28408526/-68-ga-or-18-f-for-prostate-cancer-imaging
#15
Claudia Kesch, Clemens Kratochwil, Walter Mier, Klaus Kopka, Frederik L Giesel
No abstract text is available yet for this article.
May 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28349676/flourodeoxyglucose-positron-emission-tomography-scan-may-be-helpful-in-the-case-of-ductal-variant-prostate-cancer-when-prostate-specific-membrane-antigen-ligand-positron-emission-tomography-scan-is-negative
#16
Louise M McEwan, David Wong, John Yaxley
Gallium-68 prostate specific membrane antigen ligand (Ga-68 PSMA) positron emission tomography/computed tomography (PET/CT) scanning is emerging as a useful imaging modality for the staging of suspected and known recurrent or metastatic prostate cancer and in staging of newly diagnosed higher grade prostate cancer. However, we have observed at our institution that in some cases of the more aggressive ductal variant, Ga-68 PSMA uptake has sometimes been poor compared with prominent 18-flourodeoxyglucose (F-18 FDG) avidity seen in F-18 FDG PET/CT, which would suggest that FDG PET/CT scans are important in staging of ductal pattern prostate cancer...
August 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28267455/gallium-68-prostate-specific-membrane-antigen-pet-imaging
#17
REVIEW
Michael S Hofman, Amir Iravani
The role of gallium-68 ((68)Ga) prostate-specific membrane antigen (PSMA) PET imaging is evolving and finding its place in the imaging armamentarium for prostate cancer (PCa). Despite the progress of conventional imaging strategies, significant limitations remain, including identification of small-volume disease and assessment of bone. Clinical studies have demonstrated that (68)Ga-PSMA is a promising tracer for detection of PCa metastases, even in patients with low prostate-specific antigen. To provide an accurate interpretation of (68)Ga-PSMA PET/computed tomography, nuclear medicine specialists and radiologists should be familiar with physiologic (68)Ga-PSMA uptake, common variants, patterns of locoregional and distant spread of PCa, and inherent pitfalls...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28197764/new-frontiers-in-prostate-cancer-imaging-clinical-utility-of-prostate-specific-membrane-antigen-positron-emission-tomography
#18
REVIEW
Asim Afaq, Deepak Batura, Jamshed Bomanji
Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a relatively new method of imaging prostate cancer that increases diagnostic accuracy in detecting and guiding management in various stages of the disease pathway. Gallium-68-labelled PSMA PET has increased the sensitivity of detection of disease recurrence at low PSA levels, thus allowing an optimal window for salvage treatment. Apart from its use in disease recurrence, PSMA PET has the potential for increasing sensitivity and specificity for primary tumour localisation and in detecting lymph node disease, leading to a more accurate initial staging of the condition...
May 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28034291/radiopharmaceuticals-for-diagnosis-and-therapy-of-neuroendocrine-differentiated-prostate-cancer
#19
Giampiero Giovacchini, Elisabetta Giovannini, Mattia Riondato, Andrea Ciarmiello
Neuroendocrine differentiation of prostate cancer (PCa) is a relatively frequent event, generally understudied, that carries important prognostic information. It is most frequently observed during the advanced stages of disease, when PCa has lost its sensitivity to androgen deprivation therapy or to chemotherapy, moderate to diffuse bone metastatic spread dominates the imaging scenario and it is responsible for painful clinical symptomatology. However, evidences indicate that neuroendocrine differentiation is a progressive phenomenon that starts at the very early part of the pathogenesis of cancer transformation contributing to it...
December 29, 2016: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/27771904/pilot-study-use-of-gallium-68-psma-pet-for-detection-of-metastatic-lesions-in-patients-with-renal-tumour
#20
Handoo Rhee, John Blazak, Chui Ming Tham, Keng Lim Ng, Benjamin Shepherd, Malcolm Lawson, John Preston, Ian Vela, Paul Thomas, Simon Wood
BACKGROUND: In this study, we prospectively evaluate the diagnostic potential of a gallium-68 (68Ga) prostate-specific membrane antigen (PSMA)-binding ligand and positron emission tomography (PET) in detecting metastatic lesions in patients with renal tumour. The secondary aim was to determine whether the findings would result in the alteration of patient management. RESULTS: Ten patients with renal lesion and potential metastatic disease on conventional imaging were recruited...
December 2016: EJNMMI Research
keyword
keyword
104755
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"